Page 2 - கோணம் ப்ல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கோணம் ப்ல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கோணம் ப்ல் Today - Breaking & Trending Today

Angle losses widen in H1 on increased investment spend | 29 April 2021

Angle losses widen in H1 on increased investment spend ....

Angle Plc , Lon Agl , Agl L , கோணம் ப்ல் ,

Angle completes patient enrolment for ovarian cancer clinical verification study | 26 April 2021

26 April 2021 | 09:20am
StockMarketWire.com - Liquid biopsy company Angle said it had completed patient enrolment for its ovarian cancer clinical verification study, with headline results expected in the fourth quarter of 2021.
The study would support the launch of an ovarian cancer test from Angle s clinical laboratories in the United States and the UK.
The study is designed to evaluate the use of Angle s Parsortix system for circulating tumour cell harvest and subsequent downstream analysis with Angle s HyCEAD multiplex RNA platform as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass prior to surgery. ....

United States , United Kingdom , Angle Plc , Lon Agl , Agl L , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , கோணம் ப்ல் ,

Angle wins maiden pharma services contract worth $1.2m | 16 April 2021

16 April 2021 | 07:54am
StockMarketWire.com - Liquid biopsy company Angle said it had won its first pharma services contract worth $1.2 million over 18 months with scope for further contracts from the same customer.
The customer would use the company s parsortix system in cancer drug trials for liquid biopsy longitudinal monitoring.
The work related to a phase 3 prostate cancer study and two smaller phase I studies. The phase I studies, if successful, could progress to larger phase II studies and, if successful, much larger phase III studies, the company said.
The services cover the capture, harvest and analysis of circulating tumor cells (CTCs) and CTC clusters. Samples are being shipped from multiple study centres to ANGLE s clinical laboratories in the UK and United States for analysis using the Parsortix system, it added. ....

United States , United Kingdom , Angle Plc , Lon Agl , Agl L , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , கோணம் ப்ல் ,

Global Liquid Biopsy Market Review 2019-2020 and Forecast 2021-2025 with Profiles of Over 200 Competitors

Share this article
Share this article
ResearchAndMarkets.com s offering.
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted).
Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populations; cancer screening and early detection; and recurrence monitoring for cancer patients.
Biomarker types of most interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable the detection of biomarker ....

United States , Diamir Bio , Cegat Gmbh , Pacific Biosciences , Cambridge Epigenetix , Twinstrand Biosciences , Telexos Gmbh , Codiak Biosciences , Capio Biosciences , Circulogene Theranostics , Laura Wood , Koninklijke Philips , Sysmex Inostics Gmbh , Apostle Inc , Burning Rock Biotech Ltd , Quantapore Inc , Biofluidica Inc , Namocell Inc , Nrichdx Inc , Dnanexus Inc , Seracare Life Sciences Inc , Id Solutions , Yikon Genomics Co Ltd , Labrinth Biotech Inc , Exosome Sciences Inc , Quantgene Inc ,

Angle flags potential delay in US clearance for Parsotix after FDA issues further information request | 4 March 2021

4 March 2021 | 10:11am
StockMarketWire.com - Liquid biopsy company Angle said it was likely that US clearance for Parsortix would occur later than initially expected after the company received a request to supply further information from the US Food and Drug Administration.
The company said it was likely clearance would occur in the second half of 2021 rather than the previous guidance of the earliest prospect of FDA clearance being Q2 CY21 .
Some of the technical information requested necessitates some targeted additional analytical studies, it added.
However, these additional analytical studies do not require patient samples and ANGLE anticipates that the necessary studies, which are already at an advanced planning stage, can be completed and the response submitted by early May. ....

Drug Administration , Angle Plc , Lon Agl , Agl L , கோணம் ப்ல் ,